Evidence map›Paper›PMID 19793184›Full record

ArticleChemical biology & drug design2009

Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates.

Mare Cudic, Gayle D Burstein, Gregg B Fields, Janelle Lauer-Fields

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Expression Profiling ofIranian journal of public health · 2023
    Article
  2. Article
  3. Review
  4. Review
  5. ADAMTS-18: a metalloproteinase with multiple functions.Frontiers in bioscience (Landmark edition) · 2014
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mare CudicDepartment of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, 33431, USA.
Gayle D Burstein
Gregg B Fields
Janelle Lauer-Fields
The University of Texas Health Science Center at San Antonio · USFlorida Atlantic University · US

Funding

Institutional Research Training GrantT32DE014318 · NIDCR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Kenneth M Hargreaves · 2002 to 2026
$12.1M
Mechanism &Inhibition of Collagenolytic ActivityR01CA098799 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FIELDS, GREGG B · 2003 to 2017
$4.5M
NCI NIH HHS CA98799NCI NIH HHS R01 CA098799NIDCR NIH HHS DE14318NIDCR NIH HHS T32 DE014318
6 · The paper itself

Abstract

Polyphenolic natural products from green tea and red wine have been identified as metalloproteinase inhibitors. Members from the flavonoid and stilbene families found to possess metalloproteinase inhibitory activities include (-)-epigallocatechin gallate, (-)-epicatechin gallate and piceatannol, but their minimally active pharmacophores have not been evaluated. The present study has examined compounds that are structural components of or structurally related to (-)-epigallocatechin gallate, (-)-epicatechin gallate and piceatannol for inhibition of aggrecanases and four representative matrix metalloproteinases. Piceatannol and pyrogallol were found to inhibit all aggrecanases and matrix metalloproteinases studied, indicating a crucial reliance on multiple hydroxyl groups for (-)-epigallocatechin gallate, (-)-epicatechin gallate and piceatannol activity. Differences in K(i) values for pyrogallol as determined with two structurally distinct substrates indicated the likelihood that this compound binds in a non-competitive modality. Further analysis showed that pyrogallol acts as an exosite inhibitor, consistent with the action of (-)-epigallocatechin gallate. In contrast, piceatannol was shown to be a competitive binding inhibitor and showed no differences in apparent K(i) values as determined by distinct substrates, illustrating the benefits of using two structurally distinct substrates to assist the analysis of protease inhibitors. The compounds identified here could be utilized to develop novel metalloproteinase probes or as fragment components of more active inhibitors.

Indexed as

ADAM ProteinsADAMTS4 ProteinADAMTS5 ProteinAmino Acid SequenceAntioxidantsCatechinEnzyme ActivationEnzyme InhibitorsFlavonoidsHumansMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMolecular Sequence DataMolecular StructurePeptidesProcollagen N-Endopeptidase3,3',4,5'-tetrahydroxystilbeneADAM ProteinsADAMTS4 ProteinADAMTS4 protein, humanADAMTS5 ProteinADAMTS5 protein, humanAntioxidantsCatechinEnzyme Inhibitorsepigallocatechin gallateFlavonoidsMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesPeptidesProcollagen N-EndopeptidaseStilbenes

Identifiers

PMID19793184
PMCPMC2782546
OpenAlexW2140242971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.